Janssen-Cilag Ltd.
A Real-world Study in Participants With Smoldering Multiple Myeloma
- Conditions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06472778
- Locations
- ๐ซ๐ท
CHU Montpellier, Montpellier, France
๐ซ๐ทCH Rene Dubos, Pontoise cedex, France
๐ฎ๐นAzienda Ospedaliera Universitaria Careggi, Firenze, Italy
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT06408935
- Locations
- ๐จ๐ฆ
Western University & London Health Sciences Centre, London, Ontario, Canada
๐ฉ๐ชCharite Universitatsmedizin Berlin, Berlin, Germany
๐ฉ๐ชMedizinisches Versorgungszentrum (MVZ) Dachau, Dachau, Germany
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT06285318
- Locations
- ๐ฌ๐ง
Guys and St Thomas NHS Foundation Trust, London, United Kingdom
๐ฌ๐งUniversity College Hospital, London, United Kingdom
๐ฉ๐ชUniversitatsklinikum Carl Gustav Carus Dresden, Dresden, Germany
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05901649
- Locations
- ๐ฉ๐ช
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany
๐ฆ๐นKlinikum Wels Grieskirchen, Wels, Austria
๐ฆ๐นAkh Wien, Wien, Austria
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT05347095
- Locations
- ๐ฏ๐ต
Osaka University Hospital, Suita, Japan
๐ฏ๐ตKyorin University Hospital, Tokyo, Japan
๐ฏ๐ตIeda Hospital, Toyota, Japan
Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05125679
- Locations
- ๐ฌ๐ท
Attikon Hospital, Athens, Greece
๐ฎ๐นOspedale San Giovanni di Dio, Cagliari, Italy
๐ฉ๐ชUniversitatsklinikum Frankfurt, Frankfurt, Germany
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 183
- Registration Number
- NCT04829318
- Locations
- ๐ฆ๐ท
Sanatorio Prof Leon S Morra S A, Cordoba, Argentina
๐ฆ๐ทInstituto de Neurociencias San Agustin, La Plata, Argentina
๐จ๐ฟA Shine S R O, Plzen, Czechia
A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency
- Conditions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT04829669
- Locations
- ๐ฌ๐ง
Greater Manchester Mental Health NHSFT, Manchester, United Kingdom
A Study to Evaluate the Impact of Care4Todayยฎ IBD, a Smart System to Facilitate the Management of Crohn's Disease by Patients and Health Care Providers
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04232228
- Locations
- ๐ฌ๐ง
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 254
- Registration Number
- NCT04035226
- Locations
- ๐ช๐ธ
Hosp. Puerta Del Mar, Cadiz, Spain
๐บ๐ธThe Ohio State University, Columbus, Ohio, United States
๐ฎ๐นUniversita degli Studi di Padova - Azienda Ospedaliera di Pa, Padova, Italy